A major shift in pharmaceutical research is unfolding as Cognizant prepares to introduce and implement Benchling’s AI platform at Kyowa Kirin’s Tokyo and Fuji Research Parks. This partnership aims to integrate data management, advanced automation, and AI-driven workflows to overhaul traditional research processes.
Subscribe
Biotechnology
Cognizant and Benchling Selected as Partners to Accelerate Kyowa Kirin’s R&D
Key Takeaways:
- Cognizant teams with Benchling to enhance Kyowa Kirin’s R&D efforts
- AI-driven workflows and advanced automation are core to the initiative
- Tokyo and Fuji Research Parks stand as prime locations for this transformation
- Data management underpins automation and speedier discovery
- The announcement came via PR Newswire on August 16, 2026
Introduction
Pharmaceutical research is on the brink of a transformation, especially with emerging technologies like artificial intelligence promising more streamlined, efficient, and data-centric approaches. In an announcement made on August 16, 2026, Cognizant revealed plans to collaborate with Benchling to modernize Kyowa Kirin’s R&D operations.
Partnership and Platform
Cognizant, listed on the NASDAQ market under the symbol CTSH, will provide its technical expertise and resources to introduce and implement Benchling’s AI platform for research. The focus is to bridge disparate data sources, speed up discovery, and reduce redundancies that often hamper large-scale research initiatives.
Innovation Through AI and Automation
Central to this partnership is the drive to transform the research lifecycle using both advanced automation tools and integrated data practices. The overarching goal: enhance the pace and efficiency of R&D at Kyowa Kirin by leveraging AI-driven workflows that can adapt to evolving research needs.
Focus on Japan’s Research Parks
Kyowa Kirin’s Tokyo Research Park and Fuji Research Park serve as the testing grounds for this ambitious endeavor. These sites are poised to benefit from the latest in scientific data management and process automation, ultimately helping to streamline daily laboratory work.
Implications for the Future
By combining Cognizant’s expertise in digital transformation with Benchling’s AI capabilities, Kyowa Kirin anticipates faster research cycles and improved R&D outcomes. Although details remain limited to the partnership’s initial scope, the initiative holds promise for broader shifts in global pharmaceutical research—emphasizing the growing influence of technology in healthcare innovations.
